TROP2、p-ERK1/2和Cyclin D1在胆囊癌组织中的表达及临床意义

李新星; 滕世峰; 徐楷; 张言言; 张卫刚; 张宪文; 姚骏; 姚厚山; 黄歆; 胡志前

doi:10.3969/j.issn.1001-5256.2017.05.024

TROP2、p-ERK1/2和Cyclin D1在胆囊癌组织中的表达及临床意义

DOI: 10.3969/j.issn.1001-5256.2017.05.024

第二军医大学附属长征医院普外一科

基金项目:

国家青年科学基金资助(8140101730)；

详细信息

中图分类号: R735.8
计量
- 文章访问数: 2317
- HTML全文浏览量: 40
- PDF下载量: 432
- 被引次数: 10
出版历程
- 出版日期: 2017-05-20

Expression of trophoblast cell-surface antigen 2, phosphorylated extracellular signal-regulated kinase 1/2, and cyclin D1 in gallbladder carcinoma tissue and related clinical significance

First Department of General Surgery, Changzheng Hospital, Second Military Medical University

Research funding:

摘要

摘要:
目的探讨胆囊癌组织中人滋养层细胞表面抗原（TROP）2、磷酸化细胞外信号调节激酶（p-ERK）1/2和细胞周期蛋白D1（Cyclin D1）的表达及其与临床病理参数之间的关系,并分析其与胆囊癌患者预后的关系。方法搜集第二军医大学附属长征医院2005年6月-2010年6月确诊并获取病理标本的胆囊癌患者88例,采用免疫组化法检测88例胆囊癌组织及15例癌旁组织中TROP2、p-ERK1/2和Cyclin D1蛋白的表达。计数资料采用χ2检验,Spearman检验法分析TROP2、p-ERK1/2和Cyclin D1间相关性;单因素和多因素Cox回归分析胆囊癌患者预后的影响因素;Kaplan-Meier法绘制患者的生存曲线。结果 TROP2、p-ERK1/2和Cyclin D1蛋白在胆囊癌组织中的阳性表达率分别为74.30%、58.40%和55.30%,明显高于癌旁组织中的表达（5.42%、35.67%和39.87%）（P值均<0.05）。TROP2、p-ERK1/2和Cyclin D1蛋白的表达与胆囊结石、肿瘤直径、分化程度、血管神经侵犯、淋巴结转移、手术方式及...
- 胆囊肿瘤 /
- 人滋养层细胞表面抗原2 /
- 磷酸化细胞外信号调节激酶1/2 /
- 细胞周期蛋白D1 /
- 预后
Abstract:
Objective To investigate the expression of human trophoblast cell-surface antigen 2 (TROP2) , phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2) , and cyclin D1 in gallbladder carcinoma tissue and their correlation with clinicopathological parameters, as well as their association with the prognosis of patients with gallbladder carcinoma.Methods A total of 88 patients who were diagnosed with gallbladder carcinoma in Changzheng Hospital, Second Military Medical University, from June 2005 to June 2010 were enrolled, and their pathological specimens were obtained.Immunohistochemistry was used to measure the expression of TROP2, p-ERK1/2, and cyclin D1 in 88 gallbladder carcinoma tissue samples and 15 adjacent tissue samples.The chi-square test was used for comparison of categorical data between groups, and the Spearman method was used to investigate the correlation between any two parameters of TROP2, p-ERK1/2, and cyclin D1;univariate and multivariate Cox regression analyses were used to analyze the influencing factors for the prognosis of patients with gallbladder carcinoma;the Kaplan-Meier method was used to plot their survival curves.Results The positive rates of TROP2, p-ERK1/2, and cyclin D1 in gallbladder cancer tissue were 74.30%, 58.40%, and 55.30%, respectively, significantly higher than those in adjacent tissue (5.42%, 35.67% and 39.87%, respectively) (P<0.05) .The expression of TROP2, p-ERK1/2, and cyclin D1 was associated with gallstones, tumor diameter, degree of tumor differentiation, vascular and perineural invasion, lymph node metastasis, surgical procedure, and TNM stage (χ2=4.300 ~ 53.315, all P<0.05) .The expression of TROP2 was positively correlated with that of p-ERK1/2 and cyclin D1 (rs=0.402 and 0.742, both P<0.001) , and the expression of p-ERK1/2 was also positively correlated with that of cyclin D1 (rs=0.242, P=0.023) .The multivariate survival analysis showed that positive expression of TROP2 had a significant influence on 3-year survival rate (RR=2.412, 95% CI:1.186 ~ 5.126, P=0.010) .Conclusion High expression of TROP2 may be an important reason for malignant progression of gallbladder carcinoma, and highly expressed TROP2 may mediate the high expression of p-ERK1/2 and cyclin D1, resulting in the malignant progression of gallbladder carcinoma.Positive expression of TROP2 is an independent risk factor for the prognosis of patients with gallbladder carcinoma and may be an effective target for clinical intervention.
- gallbladder neoplasms /
- human trophoblast cell-surface antigen 2 /
- phosphorylated extracellular signal regulated kinase 1/2 /
- cyclin D1 /
- prognosis

HTML全文

参考文献(18)

[1]SHI JS, ZHENG JB.Further improvement in overall level of diagnosis and treatment of gallbladder cancer[J].J Clin Hepatol, 2013, 29 (6) :401-403. (in Chinese) 石景森, 郑见宝.进一步提高胆囊癌诊治的总体水平[J].临床肝胆病杂志, 2013, 29 (6) :401-403.

[2]KAKAEI F, BEHESHTIROUY S, NEJATOLLAHI SM, et al.Surgical treatment of gallbladder carcinoma:a critical review[J].Updates Surg, 2015, 67 (4) :339-351.

[3]MISRA S, CHATURVEDI A, MISRA NC, et al.Carcinoma of the gallbladder[J].Lancet Oncol, 2003, 4 (3) :167-176.

[4]MCDOUGALL AR, TOLCOS M, HOOPER SB, et al.Trop2:from development to disease[J].Dev Dyn, 2015, 244 (2) :99-109.

[5]SHVARTSUR A, BONAVIDA B.Trop2 and its overexpression in cancers:regulation and clinical/therapeutic implications[J].Genes Cancer, 2015, 6 (3-4) :84-105.

[6]CHEN MB, WU HF, ZHAN Y, et al.Prognostic value of TROP2expression in patients with gallbladder cancer[J].Tumour Biol, 2014, 35 (11) :11565-11569.

[7]LIU T, LIU Y, BAO X, et al.Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERKsignaling pathway[J].PLo S One, 2013, 8 (9) :e75864.

[8]FONG D, MOSER P, KRAMMEL C, et al.High expression of TROP2 correlates with poor prognosis in pancreatic cancer[J].Br JCancer, 2008, 99 (8) :1290-1295.

[9]SHU YJ, WENG H, YE YY, et al.SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway[J].Mo Cancer, 2015, 14 (1) :12.

[10]LIU L, YANG ZL, WANG C, et al.The expression of Notch 1 and Notch 3 in gallbladder cancer and their clinicopathological significance[J].Pathol Oncol Res, 2016, 22 (3) :483-492.

[11]ZHAO W, ZHU H, ZHANG S, et al.Trop2 is overexpressed in gastric cancer and predicts poor prognosis[J].Oncotarget, 2016, 7 (5) :6136-6145.

[12]PAK MG, SHIN DH, LEE CH, et al.Significance of Ep CAM and TROP2 expression in non-small cell lung cancer[J].World J Surg Oncol, 2012, 10:53.

[13]FONG D, SPIZZO G, GOSTNER JM, et al.TROP2:a novel prognostic marker in squamous cell carcinoma of the oral cavity[J].Mod Pathol, 2008, 21 (2) :186-191.

[14]WU H, XU H, ZHANG S, et al.Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cel carcinoma[J].Head Neck, 2013, 35 (10) :1373-1378.

[15]CUBAS R, LI M, CHEN C, et al.Trop2:a possible therapeutic target for late stage epithelial carcinomas[J].Biochim Biophys Acta, 2009, 1796 (2) :309-314.

[16]GUERRA E, TREROTOLA M, ALOISI AL, et al.The Trop-2signalling network in cancer growth[J].Oncogene, 2013, 32 (12) :1594-1600.

[17]FENG Z, CHEN J, WEI H, et al.The risk factor of gallbladder cancer:hyperplasia of mucous epithelium caused by gallstones associates with p16/Cyclin D1/CDK4 pathway[J].Exp Mol Pathol, 2011, 91 (2) :569-577.

[18]LI M, ZHANG F, WANG X, et al.Magnolol inhibits growth of gallbladder cancer cells through the p53 pathway[J].Cancer Sci, 2015, 106 (10) :1341-1350.

施引文献

期刊类型引用(9)

1.	邱鹏. ERK表达与乳腺癌临床病理特征的相关性研究. 医学理论与实践. 2022(20): 3545-3547 . 百度学术
2.	张瑞芳. 老年胆囊癌病人术后感染性并发症发生现状及危险因素分析. 护理研究. 2021(14): 2590-2592 . 百度学术
3.	吴笑英，何锦添，叶伟标. 滋养层细胞表面抗原2在鼻咽癌中的表达. 热带医学杂志. 2020(09): 1140-1142+1116 . 百度学术
4.	李正岚. 人滋养层细胞表面抗原-2、细胞周期蛋白D1表达水平对胆囊癌患者组织分化程度的影响. 临床研究. 2019(01): 24-26 . 百度学术
5.	罗军，罗利华，万子扬. 胆囊癌组织中SUMO-1和EIF-5A2的表达及意义. 河北医药. 2019(05): 768-770+775 . 百度学术
6.	彭宁，何松青，尚丽明，肖开银. GLI1、p-STAT3蛋白在胆囊癌患者中的表达情况及与临床特征的关系. 癌症进展. 2019(10): 1219-1221 . 百度学术
7.	张冬雅，郭红军，冯巍，邱海峰. MEK/ERK信号通路在上皮性卵巢癌顺铂耐药中的参与作用. 中华全科医学. 2018(09): 1490-1492 . 百度学术
8.	刘特思，吕游，闫文帝，王雪，刘小庆，朴英实，林贞花，任香善. 虫草素通过ERK1/2、Ezrin和Akt信号通路抑制胆囊癌细胞SNU-308的增殖和迁移. 中国病理生理杂志. 2018(08): 1434-1442 . 百度学术
9.	黄晓峰，张翔，宋举贤，王宇笛，唐波. Yes相关蛋白1在胆囊癌组织中的表达及其临床意义. 广西医学. 2018(23): 2764-2766 . 百度学术